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Evidence is presented that RNA molecules exist that act as extracellular messages important in the development of higher 
organisms. 
Important metabolic and regulatory roles are oc- 
casionally discovered for classes of enzymes once 
thought to be interesting only to mechanistic en- 
zymologists. For example, no sooner had en- 
zymologists ‘solved’ all of the interesting catalytic 
problems presented by proteases than proteases 
were found to play important roles in genetic 
regulation. Now, proteases are known to control 
the expression of genes, to defend against viruses, 
and perhaps to control the induction and growth 
of tumors [l]. 
Ribonuclease (RNase) may provide a similar 
story. Today, this diminutive protein (13.5 kDa) 
from the digestive system of cows is thought to be 
interesting primarily as a model to study folding, 
catalysis and evolution in proteins [2]. However, 
recent discoveries promise to revolutionize this 
view. 
Early evidence that RNases had interesting 
biological properties was uncovered 20 years ago. 
In studying the effect of actinomycin D on the 
growth of tumor cells, Sartorelli and his co- 
workers [3] noticed that the cytostatic effect of the 
drug was increased if pancreatic RNase was ad- 
ministered at the same time. The significance of 
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this synergism was not immediately apparent, and 
the result was forgotten. 
10 years later, another RNase with anti-tumor 
activity was discovered. Vescia et al. [4] showed 
that bovine seminal RNase had strong anti-tumor 
activity both in vitro and in vivo. Seminal RNase 
is a dimer [5], and hydrolyzes double-stranded 
DNA-RNA hybrids [6]. Both properties contrast 
with those of pancreatic RNase, which is a 
monomer, hydrolyzes single-stranded RNA, and 
displays little anti-tumor activity. Nevertheless, the 
two proteins are highly homologous; their se- 
quences are 81% identical, and over half of the 
amino acid substitutions are conservative. 
Shortly afterwards, Bartholeyns and Moore [7] 
at the Rockefeller University chemically cross- 
linked pancreatic RNase to prepare dimers. The 
chemically dimerized enzyme displayed increased 
catalytic activity against double-stranded nucleic 
acids. Further, the dimeric enzyme had anti-tumor 
activity, both in vitro and in vivo [8]. 
These independent discoveries did not escape the 
attention of Dr Carl Levy of the Baltimore 
Laboratory of the National Cancer Institute, who 
wrote in 1980 [9]: 
“The finding of antitumor properties associated with 
[RNase] is exciting, for the protein offers what is in many 
respects the ideal type of therapeutic agent, that is, plentiful 
supply, low price, and minimal (at least in the animals 
tested) side effects. The dimeric RNase, moreover, is highly 
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effective against a number of animal tumors in various 
chemotherapy testing programs. Many drugs have entered 
clinical trials with far fewer credentials than this enzyme has. 
Under the circumstances, serious consideration should be 
given to testing the dimer enzyme in extensive, formal 
preclinical trials.” 
Levy’s suggestion was not pursued; indeed, the 
scientific community was less than enthusiastic 
when pursuit was suggested. Turning down a fund- 
ing request to study the anti-tumor activity of 
RNase, an NIH consultant wrote in 1984: “If 
RNase had one tenth the potential as implied [by 
Levy’s comment], dozens of scientists would 
already be busily investigating. This hasn’t hap- 
pened!” [lo]. 
However, in recent years, evidence has ac- 
cumulated to suggest hat the suggestion had con- 
siderably more potential than Dr Levy’s comment 
implied. This evidence comes from the fact that 
several proteins, first identified from their unusual 
biological activities, have been shown to be 
catalytically active as RNases and structurally 
homologous to bovine pancreatic RNase. 
For example, solid tumors secrete substances to 
stimulate the growth of blood vessels, a process 
called ‘angiogenesis’. The vascularization of solid 
tumors appears necessary for their viability; solid 
tumors unable to become vascularized simply do 
not grow. On these grounds, Folkman and his co- 
workers [l l] argued for some time that inhibitors 
of angiogenesis would be potent pharmaceutical 
agents for managing solid tumors clinically. 
One such tumor angiogenesis factor was recently 
isolated and sequenced by Vallee and his co- 
workers. The results were surprising; the protein’s 
sequence is 40% identical to that of human pan- 
creatic RNase [12] and the protein is catalytically 
active as an RNase [13]. Human placental RNase 
inhibitor, a protein with a molecular mass of 
51 kDa, inhibits both the ribonucleolytic activity 
and angiogenetic activity of angiogenesis factor 
1141. 
Even more recently, RNases with other unusual 
biological activities have been found elsewhere. 
For some 60 years, it has been known that human 
eosinophils are neurotoxic. When injected in- 
tracerebrally or intrathecally into laboratory 
animals, they produce a variety of neurological 
symptoms classified as a group as the ‘Gordon 
phenomenon’ [15], a syndrome associated with 
226 
degeneration of brain tissues. At least two proteins 
from eosinophils are associated with their 
neurotoxicity, the eosinophil-derived neurotoxin 
(EDN) and the eosinophil cationic protein (ECP). 
These proteins were recently isolated [16] and par- 
tially sequenced [17]. Both were found to be 
homologous to digestive RNase; ECP was very 
recently shown to have catalytic activity as an 
RNase [18]. 
A role for these proteins in human pathology is 
not established. Proteins from eosinophils have 
antiparasitic action [ 191, and eosinophils are 
generally believed to play a role in killing foreign 
cells. However, the protein may be involved in 
human neurological disorders. 
To this list must be added scattered reports of 
biological effects of pancreatic RNase, including 
the inhibition of protein synthesis by exogenous 
RNase [20], various effects of pancreatic RNase on 
the growth of tumors [21], and the use of pan- 
creatic RNase to treat tick-borne encephalitis [22]. 
Further, there are a number of reports throughout 
the literature suggesting developmentally impor- 
tant roles for RNA molecules in many biological 
phenomena. For example, isolated reports in the 
early 1970’s showed that another tumor 
angiogenesis factor loses its angiogenic activity 
upon treatment with RNase. This fact suggests that 
this angiogenic factor itself contains RNA [23]. 
There has been little speculation concerning the 
general significance of these scattered reports. 
Thus, it is intriguing to ask the obvious question: 
Is there any plausible reason why RNase homologs 
should appear in biology with angiogenetic proper- 
ties, as a tumor growth inhibitor, and as a 
neurotoxin? 
At the very least, the homology of tumor 
angiogenic factors, inhibitors of tumor growth, 
and neurotoxins is structurally interesting. Site- 
directed mutagenesis methods now permit us to 
correlate structural differences between these six 
proteins (pancreatic, artificially dimerized pan- 
creatic, and seminal RNases, angiogenin, ECP and 
EDN) with their biological activities [24]. 
However, the question also suggests new hypo- 
theses regarding RNA in biological processes. 
The ribonucleolytic activities of these RNase 
homologs appear to be important for their 
biological action. For example, the anti-tumor ac- 
tivity of seminal RNase seems to correlate with 
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catalytic activity [4]. Further, as noted above, in- 
hibition of the RNase catalytic activity of 
angiogenin inhibits its angiogenic activity as well. 
These facts are most consistent with the notion 
that the RNase catalytic activity of these proteins 
is relevant to their biological activities. 
Only one example may contradict this notion. 
Chemically dimerized pancreatic RNase that had 
been 92% inactivated with iodoacetic acid retained 
anti-tumor activity; only after 98% of the catalytic 
activity had been destroyed by further chemical 
modification was anti-tumor activity abolished. 
The significance of this result is unclear, as exten- 
sive chemical modification with iodoacetate 
creates a species with a poorly defined chemical 
structure. Such experiments indicate the difficulty 
of drawing conclusions from chemically modified 
proteins (and the blessings of recombinant DNA 
techniques that permit clean structural modifica- 
tion of proteins). 
The RNase homologs could exert their biological 
activity either extracellularly, where they are 
delivered, or intracellularly, following transport 
across the cell membrane. Each possibility must be 
considered. Labeling studies have shown that 
many RNase homologs are transported into cells. 
Once inside, RNase homologs could conceivably 
catalyze the hydrolysis of RNA molecules critical 
to cell processes, bind to DNA, or influence the ex- 
pression of genes by influencing the rate of 
turnover of message. 
A possible model for an intracellular target is the 
inhibition of translation in vitro by angiogenin 
[25]. Another possible model is the protein (Y- 
sarcin, a RNase that inhibits translation by catalyz- 
ing the hydrolysis of a single phosphodiester bond 
in ribosomal RNA [26]. As possible support for 
RNases as DNA-binding proteins, it is interesting 
to note that RNase A and gene 5 DNA-binding 
protein from bacteriophage fd, both helix- 
destabilizing proteins, have similar tertiary struc- 
tures, and the two proteins may be homologous 
t271. 
However, there are reasons for doubting an in- 
tracellular target for RNase homologs. For exam- 
ple, seminal RNase is transported with equal 
facility into transformed and non-transformed 
cells [4]. However, it inhibits the growth of only 
transformed cells. Further, intracellular RNases 
are already present in high concentrations; thus the 
rate of degradation of biologically active mRNA 
molecules inside cells may be independent of the 
concentration of RNases. If this is true, internal- 
ized RNase, even if it is delivered near the transla- 
tion apparatus, is unlikely to affect the lifetime of 
mRNA. Finally, when RNases such as sarcin (vide 
supra) act intracellularly at the level of the 
ribosome, the biological activity appears to be 
non-specific with regard to cell type; thus, sarcins 
are generally rather toxic. This contrasts sharply 
with the rather specific biological effects produced 
by the RNase analogs discussed above. 
The selectivity of the biological activity of the 
RNases discussed above, and the dependence of 
biological activity on catalytic activity when ad- 
ministered extracellularly, suggest an alternative 
hypothesis, that these RNase homologs exert their 
biological effects by extracellular action as 
ribonucleases. This suggestion is intriguing. It im- 
plies that the substrate for extracellular RNases, 
extracellular RNA, must play a biological role in 
angiogenesis, neurological development, and other 
biological processes. This suggests the general 
hypothesis that there exists extracellular RNA 
molecules having the role of carrying information 
over short distances between cells which act as in- 
tercellular communicators during the development 
of higher organisms [28]. Further, it is consistent 
with the suggestion that certain angiogenic factors 
contain RNA [23]. 
The hypothesis of a biological role for ex- 
tracellular RNA offers an explanation for another 
fact. Extracellular fluid contains many proteins 
with RNase activity, and many proteins that are 
RNase inhibitors [29]. The biological significance 
of this balance between RNases and RNase in- 
hibitors is not known. However, it makes little 
sense in any case in the absence of a substrate for 
the RNases, extracellular RNA. We hypothesize 
that a combination of RNA, RNases and RNase 
inhibitors assists in the control of the development 
of tissues in higher organisms. By perturbing the 
distribution of extracellular RNA, the addition of 
extracellular RNases influences development, in- 
cluding the stimulation and inhibition of cell 
growth. 
Further, the chemical nature of RNA, especially 
the ease with which it forms tertiary structures and 
the ease with which it can undergo hydrolysis, 
makes it well-suited to play the role of a short 
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distance-short time messenger. Indeed, from a 
purely chemical point of view, the role of steroids 
as long distance-long time extracellular messen- 
gers, polypeptides as intermediate distance-inter- 
mediate time extracellular messengers, and RNA 
as a short distance-short time messenger seems to 
be a good match of chemistry and biological 
function. 
One final interesting feature about the evolution 
of these homologous proteins is worth noting. 
Human angiogenin is structurally more similar to 
turtle RNase than to human pancreatic RNase 
[30]. This suggests that angiogenin and conven- 
tional RNase diverged before reptiles and mam- 
mals diverged. This places the evolutionary origin 
of angiogenins before the origin of land-based life 
and, significantly, perhaps at the time of the origin 
of specific physiology found in higher organisms. 
In contrast, bovine digestive RNase appears to be 
a relative late-comer evolutionarily. It appears as if 
digestive RNases had evolved from developmental- 
ly important RNases as an adaptive response to the 
evolution of ruminant digestion. 
The hypothesis of extracellular ‘communicator 
RNAs’ involved in eukaryotic development is well 
worth testing, if only because a direct test is now 
possible. Should the hypothesis prove correct, it 
will add yet another chapter to the already growing 
resume of RNA molecules, and resurrect RNase as 
a protein interesting to biologists as well as 
mechanistic enzymologists. 
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